Charles Schwab Investment Management Inc Y M Abs Therapeutics, Inc. Transaction History

Charles Schwab Investment Management Inc

  • $557 Billion
  • Q2 2025

A detailed history of Charles Schwab Investment Management Inc transactions in Y M Abs Therapeutics, Inc. stock. As of the latest transaction made, Charles Schwab Investment Management Inc holds 278,179 shares of YMAB stock, worth $2.4 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
278,179
Previous 277,610 0.2%
Holding current value
$2.4 Million
Previous $1.23 Million 2.03%
% of portfolio
0.0%
Previous 0.0%

Shares

28 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2025

Aug 12, 2025
BUY
$3.64 - $5.35 $2,071 - $3,044
569 Added 0.2%
278,179 $1.25 Million
Q1 2025

Sep 15, 2025
SELL
$4.43 - $8.17 $2,520 - $4,648
-569 Reduced 0.2%
277,610 $1.23 Million
Q1 2025

May 09, 2025
SELL
$4.43 - $8.17 $30,699 - $56,618
-6,930 Reduced 2.44%
277,610 $1.23 Million
Q4 2024

Feb 06, 2025
BUY
$7.76 - $15.69 $38,512 - $77,869
4,963 Added 1.78%
284,540 $2.23 Million
Q3 2024

Nov 12, 2024
BUY
$9.95 - $15.39 $238,620 - $369,082
23,982 Added 9.38%
279,577 $3.67 Million
Q2 2024

Aug 12, 2024
BUY
$11.6 - $17.25 $62,292 - $92,632
5,370 Added 2.15%
255,595 $3.09 Million
Q1 2024

May 08, 2024
BUY
$6.57 - $18.69 $17,863 - $50,818
2,719 Added 1.1%
250,225 $4.07 Million
Q4 2023

Feb 06, 2024
SELL
$4.88 - $7.42 $9,457 - $14,379
-1,938 Reduced 0.78%
247,506 $1.69 Million
Q3 2023

Nov 08, 2023
SELL
$4.86 - $7.23 $37,183 - $55,316
-7,651 Reduced 2.98%
249,444 $1.36 Million
Q2 2023

Aug 09, 2023
BUY
$5.68 - $10.34 $121,864 - $221,844
21,455 Added 9.1%
257,095 $1.75 Million
Q1 2023

May 11, 2023
SELL
$2.83 - $5.11 $45,050 - $81,346
-15,919 Reduced 6.33%
235,640 $1.18 Million
Q4 2022

Feb 13, 2023
BUY
$3.0 - $15.17 $9,432 - $47,694
3,144 Added 1.27%
251,559 $1.23 Million
Q3 2022

Nov 14, 2022
BUY
$13.96 - $19.67 $11,265 - $15,873
807 Added 0.33%
248,415 $3.58 Million
Q2 2022

Aug 15, 2022
BUY
$8.22 - $15.13 $113,863 - $209,580
13,852 Added 5.93%
247,608 $3.75 Million
Q1 2022

May 13, 2022
SELL
$6.55 - $17.42 $71,971 - $191,410
-10,988 Reduced 4.49%
233,756 $2.78 Million
Q4 2021

Feb 11, 2022
BUY
$15.51 - $29.31 $79,488 - $150,213
5,125 Added 2.14%
244,744 $3.97 Million
Q3 2021

Nov 16, 2021
BUY
$27.47 - $37.31 $1.03 Million - $1.4 Million
37,500 Added 18.55%
239,619 $6.84 Million
Q2 2021

Aug 16, 2021
BUY
$25.45 - $37.64 $295,245 - $436,661
11,601 Added 6.09%
202,119 $6.83 Million
Q1 2021

May 17, 2021
BUY
$29.16 - $51.96 $380,304 - $677,662
13,042 Added 7.35%
190,518 $5.76 Million
Q4 2020

Feb 16, 2021
BUY
$37.86 - $54.26 $198,234 - $284,105
5,236 Added 3.04%
177,476 $8.79 Million
Q3 2020

Nov 13, 2020
BUY
$35.13 - $43.62 $1.1 Million - $1.37 Million
31,359 Added 22.26%
172,240 $6.61 Million
Q2 2020

Aug 14, 2020
BUY
$23.66 - $49.53 $474,927 - $994,215
20,073 Added 16.62%
140,881 $6.09 Million
Q1 2020

May 15, 2020
BUY
$14.39 - $35.8 $32,809 - $81,624
2,280 Added 1.92%
120,808 $3.15 Million
Q4 2019

Feb 07, 2020
BUY
$23.81 - $33.78 $747,014 - $1.06 Million
31,374 Added 36.0%
118,528 $3.7 Million
Q3 2019

Nov 08, 2019
BUY
$21.57 - $31.37 $456,270 - $663,569
21,153 Added 32.05%
87,154 $2.27 Million
Q2 2019

Aug 09, 2019
BUY
$19.51 - $28.31 $590,528 - $856,887
30,268 Added 84.71%
66,001 $1.51 Million
Q1 2019

May 14, 2019
SELL
$18.21 - $26.21 $30,028 - $43,220
-1,649 Reduced 4.41%
35,733 $937,000
Q4 2018

Feb 14, 2019
BUY
$15.41 - $28.92 $576,056 - $1.08 Million
37,382 New
37,382 $761,000

Others Institutions Holding YMAB

# of Institutions
89
Shares Held
25.8M
Call Options Held
24K
Put Options Held
0
View Full List

About Y-mAbs Therapeutics, Inc.

YMAB Quotes by TradingView
  • Ticker YMAB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 43,719,500
  • Market Cap $376M
  • Description
  • Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody based therapeutic products for the treatment of cancer in the United States. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment o...
More about YMAB
Track This Portfolio

Track Charles Schwab Investment Management Inc Portfolio

Follow Charles Schwab Investment Management Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Charles Schwab Investment Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Charles Schwab Investment Management Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email